
Ultragenyx Pharmaceutical (RARE)
Order type
Buy in
Order amount
Est. shares
0 shares
Buy Ultragenyx Pharmaceutical (RARE) Stock
Start investing in Ultragenyx Pharmaceutical (RARE)
About Ultragenyx Pharmaceutical (RARE)
Market cap | $3.44B |
Today's volume | 310.77K |
Revenue (TTM) | $590.69M |
Avg. daily volume | 1.06M |
EBITDA (TTM) | -$477.88M |
Open | $36.29 |
Price / earnings ratio | -6.18x |
Today's range | $35.51 - $36.95 |
Debt / equity | 616.79x |
52 week range | $29.59 - $60.37 |
5 year debt / equity | 197.01x |
Beta (LTM) | 0.89x |
Interest coverage | -8.5x |
Dividend & yield | $0.00 (0.00%) |
Current ratio | 2.4x |
Ex-dividend date | — |
Next earnings | Jul 31, 2025 |
Dividend payable date | — |
Ultragenyx Pharmaceutical Stock Rating
Ultragenyx Pharmaceutical Stock News
View all



Frequently Asked Questions (FAQ)
How to buy RARE stock on Public
- 1
Sign up for a brokerage account on Public
It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.
- 2
Add funds to your Public account
There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.
- 3
Choose how much you'd like to invest in RARE stock
Navigate to the Explore page. Then, type RARE into the search bar. When you see RARE stock appear in the results, tap it to open up the purchase screen.
- 4
Manage your investments in one place
You can find your newly purchased RARE stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets.
Ultragenyx Pharmaceutical Stock Earnings
The value each RARE share was expected to gain vs. the value that each RARE share actually gained.
Ultragenyx Pharmaceutical (RARE) reported Q1 2025 earnings per share (EPS) of -$1.57, beating estimates of -$1.64 by 4.27%. In the same quarter last year, Ultragenyx Pharmaceutical's earnings per share (EPS) was -$2.03. Ultragenyx Pharmaceutical is expected to release next earnings on 07/31/2025, with an earnings per share (EPS) estimate of -$1.33.